**人工智能医疗科技公司Carlsmed完成5250万美元C轮融资，加速个性化手术平台商业化进程**
近日，全球领先的人工智能个性化手术医疗科技公司Carlsmed宣布，成功完成了由B Capital和US Venture Partners共同领投的5250万美元C轮融资。此次融资标志着该公司在医疗科技领域的创新步伐进一步加快。
Carlsmed表示，筹集到的资金将主要用于aprevo ®个性化脊柱手术平台的商业化进程，该平台专注于腰椎融合手术。同时，这笔资金还将投入到aprevo ®颈椎融合手术平台的研发中，该平台预计将于2025年正式推出，为医疗行业带来更先进的手术解决方案。
aprevo ®平台利用人工智能技术，为医生提供精准的手术规划和执行工具，以实现更个性化、更安全的手术过程。Carlsmed的这一创新技术有望改变脊柱手术的标准，提高手术成功率，减少并发症，并缩短患者康复时间。
此次B Capital和US Venture Partners的领投，显示了投资界对Carlsmed技术潜力和市场前景的高度认可。随着医疗科技的不断发展，人工智能在医疗领域的应用正日益广泛，Carlsmed的个性化手术解决方案有望引领行业新风尚。
Carlsmed将继续致力于研发和创新，以满足全球医疗市场对精准医疗和个性化治疗日益增长的需求。通过此次融资，公司将进一步扩大其市场影响力，为更多患者带来福音，同时也为全球医疗健康领域带来革命性的变化。
英语如下：
**News Title:** “Carlsmed Raises $52.5 Million in Series C Funding to Accelerate aprevo ® Platform for Personalized Surgery”
**Keywords:** Carlsmed, Artificial Intelligence, Surgical Platform
**News Content:**
Leading artificial intelligence (AI) medical technology company Carlsmed has announced the successful completion of a $52.5 million Series C funding round, co-led by B Capital and US Venture Partners. This financing round signifies an acceleration in the company’s innovation within the medical technology sector.
Carlsmed states that the funds raised will predominantly support the commercialization of its aprevo ® personalized spinal surgery platform, focused on lumbar fusion surgeries. Additionally, the capital will contribute to the development of the aprevo ® cervical fusion surgery platform, expected to launch in 2025, offering advanced surgical solutions to the healthcare industry.
The aprevo ® platform harnesses AI to provide surgeons with precise planning and execution tools for more personalized and safer surgical procedures. Carlsmed’s innovative technology has the potential to redefine standards in spinal surgery, enhancing success rates, reducing complications, and shortening patients’ recovery times.
The investment from B Capital and US Venture Partners underscores the confidence in Carlsmed’s technological potential and market prospects. As medical technology continues to evolve, the application of AI in healthcare is expanding, and Carlsmed’s personalized surgical solutions are poised to set new industry trends.
Carlsmed remains committed to research and innovation to cater to the growing global demand for precision medicine and individualized treatments. With this funding, the company aims to amplify its market presence, benefiting more patients and driving transformative changes in the global healthcare landscape.
【来源】https://www.businesswire.com/news/home/20240318820510/en/Carlsmed-Raises-52.5M-in-Series-C-Financing-to-Advance-Personalized-Spine-Surgery
Views: 1